Annual accounts receivable:
$405.31M+$77.52M(+23.65%)Summary
- As of today (May 29, 2025), ALNY annual accounts receivable is $405.31 million, with the most recent change of +$77.52 million (+23.65%) on December 31, 2024.
- During the last 3 years, ALNY annual accounts receivable has risen by +$206.74 million (+104.11%).
- ALNY annual accounts receivable is now at all-time high.
Performance
ALNY Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$418.04M+$12.73M(+3.14%)Summary
- As of today (May 29, 2025), ALNY quarterly accounts receivable is $418.04 million, with the most recent change of +$12.73 million (+3.14%) on March 31, 2025.
- Over the past year, ALNY quarterly accounts receivable has increased by +$96.66 million (+30.08%).
- ALNY quarterly accounts receivable is now at all-time high.
Performance
ALNY Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ALNY Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +23.6% | +30.1% |
| 3 y3 years | +104.1% | +167.1% |
| 5 y5 years | +842.3% | +453.2% |
ALNY Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +104.1% | at high | +193.8% |
| 5 y | 5-year | at high | +842.3% | at high | +504.8% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
ALNY Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $418.04M(+3.1%) |
| Dec 2024 | $405.31M(+23.6%) | $405.31M(+14.5%) |
| Sep 2024 | - | $353.85M(+14.3%) |
| Jun 2024 | - | $309.48M(-3.7%) |
| Mar 2024 | - | $321.38M(-2.0%) |
| Dec 2023 | $327.79M(+37.7%) | $327.79M(+0.7%) |
| Sep 2023 | - | $325.44M(+47.5%) |
| Jun 2023 | - | $220.63M(+0.5%) |
| Mar 2023 | - | $219.43M(-7.8%) |
| Dec 2022 | $237.96M(+19.8%) | $237.96M(+29.0%) |
| Sep 2022 | - | $184.51M(+29.7%) |
| Jun 2022 | - | $142.27M(-9.1%) |
| Mar 2022 | - | $156.53M(-21.2%) |
| Dec 2021 | $198.57M(+93.9%) | $198.57M(+40.8%) |
| Sep 2021 | - | $141.06M(-3.8%) |
| Jun 2021 | - | $146.59M(+32.5%) |
| Mar 2021 | - | $110.63M(+8.0%) |
| Dec 2020 | $102.41M(+138.1%) | $102.41M(+29.4%) |
| Sep 2020 | - | $79.12M(+14.5%) |
| Jun 2020 | - | $69.11M(-8.5%) |
| Mar 2020 | - | $75.57M(+75.7%) |
| Dec 2019 | $43.01M(+129.3%) | $43.01M(-10.6%) |
| Sep 2019 | - | $48.11M(+56.5%) |
| Jun 2019 | - | $30.74M(-9.1%) |
| Mar 2019 | - | $33.80M(+80.2%) |
| Dec 2018 | $18.76M(-44.8%) | $18.76M(+458.0%) |
| Sep 2018 | - | $3.36M(+13.5%) |
| Jun 2018 | - | $2.96M(-94.2%) |
| Mar 2018 | - | $50.77M(+49.3%) |
| Dec 2017 | $34.00M(+45.7%) | $34.00M(+132.2%) |
| Sep 2017 | - | $14.64M(-4.9%) |
| Jun 2017 | - | $15.40M(-20.8%) |
| Mar 2017 | - | $19.46M(-16.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $23.33M(+181.2%) | $23.33M(+54.1%) |
| Sep 2016 | - | $15.15M(+59.2%) |
| Jun 2016 | - | $9.51M(+7.9%) |
| Mar 2016 | - | $8.81M(+6.2%) |
| Dec 2015 | $8.30M(-79.2%) | $8.30M(+2.1%) |
| Sep 2015 | - | $8.13M(-13.5%) |
| Jun 2015 | - | $9.40M(-7.0%) |
| Mar 2015 | - | $10.11M(-74.7%) |
| Dec 2014 | $39.94M(+840.1%) | $39.94M(>+9900.0%) |
| Sep 2014 | - | $384.00K(+331.5%) |
| Jun 2014 | - | $89.00K(-45.7%) |
| Mar 2014 | - | $164.00K(-96.1%) |
| Dec 2013 | $4.25M(+3984.6%) | $4.25M(+597.5%) |
| Sep 2013 | - | $609.00K(+32.4%) |
| Jun 2013 | - | $460.00K(-17.6%) |
| Mar 2013 | - | $558.00K(+436.5%) |
| Dec 2012 | $104.00K(-92.9%) | $104.00K(-92.9%) |
| Dec 2011 | $1.47M(-57.4%) | $1.47M(-27.6%) |
| Sep 2011 | - | $2.03M(+55.0%) |
| Jun 2011 | - | $1.31M(+13.7%) |
| Mar 2011 | - | $1.15M(-66.7%) |
| Dec 2010 | $3.45M(-42.9%) | $3.45M(-42.9%) |
| Dec 2009 | $6.04M(+57.8%) | $6.04M(+17.8%) |
| Sep 2007 | - | $5.13M(-8.7%) |
| Jun 2007 | - | $5.62M(+27.8%) |
| Mar 2007 | - | $4.39M(+14.7%) |
| Dec 2006 | $3.83M(+528.7%) | $3.83M(-21.0%) |
| Sep 2006 | - | $4.85M(+35.0%) |
| Jun 2006 | - | $3.59M(+15.2%) |
| Mar 2006 | - | $3.12M(+411.7%) |
| Dec 2005 | $609.00K(-29.1%) | $609.00K(+100.3%) |
| Sep 2005 | - | $304.00K(-55.2%) |
| Jun 2005 | - | $679.00K(-21.0%) |
| Dec 2004 | $859.00K | $859.00K |
FAQ
- What is Alnylam Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual accounts receivable year-on-year change?
- What is Alnylam Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Alnylam Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of ALNY is $405.31M
What is the all time high annual accounts receivable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual accounts receivable is $405.31M
What is Alnylam Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, ALNY annual accounts receivable has changed by +$77.52M (+23.65%)
What is Alnylam Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of ALNY is $418.04M
What is the all time high quarterly accounts receivable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly accounts receivable is $418.04M
What is Alnylam Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, ALNY quarterly accounts receivable has changed by +$96.66M (+30.08%)